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Metabolic syndrome (MetS) is deﬁned as cluster of multiple meta-
bolic and cardiovascular (CV) abnormalities included abdominal
obesity, high-normal blood pressure, dyslipidaemia, and impaired
fasting glucose tolerance that exhibits has a growing prevalence
worldwide. We investigated whether an elevated level of osteopro-
tegerin (OPG) predicts imbalance between different phenotypes of
circulating endothelial (EPCs) and mononuclear (MPCs) progenitor
cells in MetS patients. We have analyzed data regarding dysmetabolic
disorder subjects without known CV disease), as well as with known
type two diabetes mellitus. All patients have given their informed
written consent for participation in the study. This article contains
data on the independent predictors of depletion in numerous of
circulating EPCs and MPCs in MetS patients. The data are supple-
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Value of the data
 Previously unreported a predictive value of elevated OPG level in metabolic syndrome patients
without known cardiovascular disease on number of circulating endothelial and mononuclear-
derived progenitor cells.
 May improve predictive models based on several biomarkers including dyslipidemia, galectin-3,
and HOMA-IR in metabolic syndrome patients.
 May stimulate the novel research regarding clinical utility of osteoprotegerin level as predictive
biomarker of endothelial dysfunction and cardiovascular events.1. Data
The mean serum level of OPG among entire MetS patients’ cohort was 11427186 pg/mL vs.
245775 pg/mL in the healthy individuals (po0.001). Patients with MetS were divided in to two
subgroups depended on serum level of OPG using mean value as cutoff point). Subjects with OPG
level o 1142 pg/mL and Z1142 pg/mL were included in cohorts with lower (n¼18) and higher
(n¼29) OPG level, respectively.
In multivariate logistic regression analysis we found that OPG, dyslipidemia, galectin-3, and
HOMA-IR were independent predictors for depletion in numerous of circulating EPCs and MPCs
alone, as well as combined variable: EPCs and MPCs (Fig. 1), whereas the comparison of pre-
dictive models based on several biomarkers including dyslipidemia, galectin-3, and HOMA-IR
has shown a lack of advantages of these models versus predictive model constructed on OPG
alone (Table 2).
Fig. 1. (A) The independent predictors of depletion in numerous of circulating CD45-/CD34þ EPCs. The results of age-, gender-,
and BMI-adjusted multivariate logistic regression analysis. (B) The independent predictors of depletion in numerous of cir-
culating CD14þCD309þ MPCs. The results of age-, gender-, and BMI-adjusted multivariate logistic regression analysis. (C) The
independent predictors of depletion in numerous of circulating CD14þCD309þTie2þ MPCs. The results of age-, gender-, and
BMI-adjusted multivariate logistic regression analysis. (D) The independent predictors of depletion in numerous of circulating
EPCs and MPCs (combined variables). The results of age-, gender-, and BMI-adjusted multivariate logistic regression analysis.
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2.1. Study design
The results present data regarding 47 patients with MetS who were examined in three our centers
between February 2013 and November 2013. We enrolled dysmetabolic disorder subjects without
known CV disease including angina pectoris, asymptomatic atherosclerosis (negative contrast-
enhanced multispiral tomography angiography), as well as known T2DM. Data received from 35
healthy volunteers were used as a negative control to verify the changes of OPG level and circulating
EPCs/MPCs. Healthy individuals were matched with MetS patients on age and sex. All patients have
given their informed written consent for participation in the study. Study design was reported
recently [1].
MetS was diagnosed based on the National Cholesterol Education Program Adult Treatment Panel
III criteria [2].
2.2. Anthropometric measurements and smoking status
Anthropometric measurements (body mass, waist circumference, weight, and waist-to-hip ratio)
were made using standard procedures. Current smoking was deﬁned as consumption of one cigarette
daily for three months.
2.3. Echocardiography and Doppler imaging
Transthoracic B-mode echocardiography and Tissue Doppler Imaging were performed according to
a conventional procedure on ACUSON scanner (SIEMENS, Germany) using phased probe with
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were measured by modiﬁed Simpson's method [3].
LV mass was estimated using formula recommended American Society of Echocardiography's
Guidelines and Standards Committee and the Chamber Quantiﬁcation Writing Group [4]. LV
hypertrophy (LVH) was deﬁned as a LV mass/body surface area (BSA) Z96 g/m2, for women, and
Z116 g/m2, for men [5].
2.4. Cardiovascular risk calculation
A 10-year cardiovascular risk for study patients was calculated using the Framingham General
Cardiovascular Risk Score (2008) [6] by on-line calculator.
2.5. MetS Z-score calculation
The MetS Z score was calculated using the online calculator (http://mets.health-outcomes-policy.
uﬂ.edu/calculator/) [7].
2.6. Calculation of glomerular ﬁltration rate
Glomerular ﬁltration rate (GFR) was calculated with CKD-EPI formula [8].
2.7. Measurement of circulating biomarkers
To determine circulating biomarkers, blood samples were collected at baseline in the morning (at
7–8 a.m.) into cooled silicone test tubes wherein 2 mL of 5% Trilon B solution were added. Then they
were centrifuged upon permanent cooling at 6000 rpm for 3 min. Plasma was collected and refri-
gerated immediately to be stored at a temperature 70 °С. Serum OPG, Receptor activator of nuclear
factor kappa-B ligand (RANKL), and adiponectin were measured by high-sensitive enzyme-linked
immunosorbent assays using commercial kits (R&D Systems GmbH, Wiesbaden-Nordenstadt,
Germany) according to the manufacturers’ recommendations.
High-sensitive C-reactive protein (hs-CRP) was measured by commercially available standard kit
(R&D Systems GmbH, Wiesbaden-Nordenstadt, Germany).
Fasting insulin level was measured by a double-antibody sandwich immunoassay (Elecsys 1010
analyzer, F. Hoffmann-La Roche Diagnostics, Mannheim, Germany). Insulin resistance was assessed by
the homeostasis model assessment for insulin resistance (HOMA-IR) [9] using the following formula:
HOMA-IR (mmol/L mU/mL)¼fasting glucose (mmol/L) fasting insulin (mU/mL)/22.5
IR was arbitrarily deﬁned as a homeostasis model assessment-IR index (HOMA-IR) value above the
75th percentile of normal glucose tolerance equal 2.45 mmol/LmU/mL.
Hemoglobin A1c (HbA1c) were determined by high-pressure liquid chromatography method.
Concentrations of total cholesterol (TC), cholesterol of high-density lipoproteins (HDL-C), triglycerides
(TG), and low-density lipoproteins (LDL-C) were measured by direct enzymatic method (Roche P800
analyzer, Basel, Switzerland).
2.8. Blood sampling for measurement f circulating endothelial progenitor cells and mononuclear pro-
genitor cells
Blood samples were received from peripheral vein in blood collection tubes. Each sample contains
75 mL into 1 mL PBS containing 5 mM EDTA (10 mL of 0.5 M stock). To prevent clotting samples were
mixed immediately. Peripheral blood mononuclear cells were removed using density gradient cen-
trifugation with Ficoll-Paque (Miltenyi Biotec Inc., Germany). After layer 35 mL of diluted cell sus-
pension over 15 mL of Ficoll-Paque in a 50 mL conical tub all blood samples with anticoagulants
(EDTA) have centrifuged at 400 g for 30–40 min at 20 °C in a swinging-bucket rotor without brake.
The upper layer leaving the mononuclear cell layer was aspirated to prevent a contamination of
samples before measurement of real EPCs.
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have the samples washed twice with PBS and ﬁxed immediately.
2.9. Determination of circulating EPCs
The ﬂow cytometric technique (FCT) was used for predictably distinguishing circulating cell
subsets, which depend on expression of CD45, CD34, CD14, Tie-2, and VEGFR2, using High-Deﬁnition
Fluorescence Activated Cell Sorter (HD-FACS) methodology [10].
2.10. Statistical analysis
Statistical analysis of the results obtained was performed in SPSS system for Windows, Version 22
(SPSS Inc, Chicago, IL, USA). The data were presented as mean (М) and standard deviation (7SD) or
95% conﬁdence interval (CI); as well as median (Ме) and 25–75% interquartile range (IQR). To com-
pare the main parameters of patient cohorts, two-tailed Student t-test or Shapiro–Wilk U-test were
used. To compare categorical variables between groups, Chi2 test (χ2) and Fisher F exact test were
used. Predictors of EPCs in patients were examined in multivariable regression analysis. C-statistics,
integrated discrimination indices (IDI) and net-reclassiﬁcation improvement (NRI) were utilized
for prediction performance analyses. A two-tailed probability value of o0.05 was considered as
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